CompletedNCT01177943
A Bioequivalence (BE) Study in Healthy Subjects
Medication studyAges 20–55JapanADHD
Understand this study
Who was this study for?
Listed age limits: 20 years to 55 years.
- Listed locations
- FukuokaSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateAugust 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 42
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Japan
- Age range
- From 20 Years to 55 Years
- Official registry ID
- NCT01177943
- Official title
Show the full official title
LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects
Get this study by email
Recruitment & locations
CompletedFukuoka
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
Listed age limits: 20 years to 55 years.
